Inovio Pharmaceuticals Inc

Inovio insider trades reveal CMO Sumner John’s confidence, buying 4,292 shares from vested RSUs while selling a portion for tax; a bullish signal amid legal risk and market volatility.

Inovio’s insider buying spree signals strong confidence in its DNA‑vaccine pipeline—learn how CEO moves, Akeso partnership, and future milestones could boost value.

Inovio’s February 2026 insider trades reveal a strategic shift: executives balance liquidity with confidence in its DNA‑based vaccine pipeline, highlighting market access, pricing, and partnership challenges amid growing competition.